TNFRSF1A links the compounds to TNF–signaling, one of the most validated therapeutic pathways in RA, while CXCL12 indicates the modulation of chemokine signaling and immune cell recruitment into inflamed joints, which suggests that the isolated compounds may exert therapeutic effects primarily through the regulation of multiple inflammatory pathway signaling (via TNFRSF1A, RELA, and NFKB1) [26], leukotriene metabolism and immune cell activation (via ALOX5), and cytokine/chemokine signaling (via CXCL12 and PTGS1) [27]. The gene discussed is RELA; the disease is rheumatoid arthritis.